Novartis to acquire Excellergy to strengthen next-generation anti-IgE pipeline
Friday, March 27, 2026
Novartis has agreed to acquire Excellergy, Inc., a private biotechnology company focused on developing next-generation anti-IgE therapies for IgE-driven diseases. The deal will add Exl-111, a high-affinity, half-life extended anti-IgE antibody currently in Phase 1 development.
The acquisition builds on Novartis’ experience in IgE biology and its established presence in the allergy treatment space. Exl-111 is designed as an advanced version of existing anti-IgE therapies and is expected to complement the company’s current allergy portfolio across multiple conditions.
Exl-111 targets IgE, a key driver of several allergic diseases. Unlike conventional therapies, it is designed to dissociate receptor-bound IgE, which may lead to faster and deeper reduction of IgE signalling. Early preclinical and Phase 1 pharmacokinetic data suggest a differentiated profile, including sustained exposure due to its extended half-life.
If confirmed in clinical studies, the therapy may offer earlier symptom relief, improved disease control, more convenient dosing, and broader use across conditions such as food allergy, chronic spontaneous urticaria, chronic inducible urticaria and allergic asthma, including potential use in paediatric patients.
Source: globenewswire.com
